Trial Profile
A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 29 Jun 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.
- 02 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Mar 2023.
- 27 Jan 2022 Planned End Date changed from 1 Sep 2021 to 1 Jun 2022.